Samantha Du, Zai Lab CEO (Zai Lab)

Saman­tha Du's Zai Lab sets its am­bi­tions sky high, look­ing to raise $750M to fu­el its li­cens­ing busi­ness mod­el

Look­ing to cap­i­tal­ize on a bustling Chi­nese drug mar­ket, up­start biotechs like Saman­tha Du’s Zai Lab have made a killing in-li­cens­ing for­eign mol­e­cules as well as de­vel­op­ing their own home­grown as­sets. Now, with even more growth in mind, Zai Lab has of­fered up a healthy chunk of shares on the US mar­ket to fu­el its am­bi­tions.

Zai Lab will of­fer $750 mil­lion in US de­pos­i­to­ry shares as part of a ma­jor cash raise to keep dri­ving its in-li­cens­ing busi­ness en­gine as well as ad­vance its suite of clin­i­cal pro­grams, the Chi­nese biotech said this week.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.